According to ARRS’ American Journal of Roentgenology (AJR), immediately reading screening mammograms during the coronavirus disease (COVID-19) pandemic promises a new and improved paradigm—reducing care disparities, while increasing the speed of diagnostic workup.

Flow Chart of Patient Selection


September 9, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), immediately reading screening mammograms during the coronavirus disease (COVID-19) pandemic promises a new and improved paradigm—reducing care disparities, while increasing the speed of diagnostic workup.

“The immediate-read screening mammography program reduced prior racial and ethnic disparities in same-day diagnostic imaging after abnormal screening mammograms,” wrote first author Brian N. Dontchos, M.D., of Massachusetts General Hospital and Harvard Medical School.

In May 2020, Dontchos et al. implemented a program wherein a dedicated breast imaging radiologist interpreted all screening mammograms in real-time, with patients receiving their results before being discharged. A separate radiologist made efforts to perform any recommended diagnostic imaging during the same visit. The team then retrospectively identified screening mammograms performed from June 1, 2019 to October 31, 2019 (pre-implementation; 8,222 examinations) or June 1, 2020 to October 31, 2020 (post-implementation; 7,235 examinations). 521 and 359 patients had abnormal screening examinations, respectively.

Before implementing this immediate-read screening mammography program, patients with races other than White had lower odds than White patients of having same-day diagnostic imaging after abnormal screening examinations (adjusted odds ratio [OR]: 0.30; 95% confidence interval [CI]: 0.10, 0.86; p=.03). After implementation, these odds were not significantly different (OR: 0.92; 95% CI: 0.50, 1.71; p=.80).

Responding to the Society of Breast Imaging’s recommendation to reduce patient hospital visits during COVID-19, “we believe the practice is sustainable and not limited to only a transient period of lower-than-normal screening volumes,” the authors of this AJR article noted.

For more information: arrs.org

 

Related COVID-19 Cancer-care Information:

Female Breast Cancer Surpasses Lung as the Most Commonly Diagnosed Cancer Worldwide

Johns Hopkins Medicine Expert Weighs Devastating Impact of COVID-19 on Healthcare Workers

Radiation Oncologists Urge Congress to Advance Bills That Protect Patient Access to Cancer Care During Pandemic

Breast Imaging in the Age of Coronavirus


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
Subscribe Now